Intermediate-dose cytarabine is an effective therapy for adults with non-Langerhans cell histiocytosis.
Cytarabine
Efficacy
Non-Langerhans cell histiocytosis
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
07 02 2022
07 02 2022
Historique:
received:
09
11
2021
accepted:
30
01
2022
entrez:
8
2
2022
pubmed:
9
2
2022
medline:
12
3
2022
Statut:
epublish
Résumé
Non-Langerhans cell histiocytosis, including Erdheim-Chester disease (ECD), Rosai-Dorfman disease (RDD), indeterminate cell histiocytosis (ICH), and unclassified histiocytosis, is a rare disorder lacking a standard treatment strategy. We report our experience using intermediate-dose cytarabine as the first or subsequent therapy in non-Langerhans cell histiocytosis. Nine ECD patients, 5 RDD patients, 1 ICH patient and 1 unclassified histiocytosis patient were enrolled. Intermediate-dose cytarabine therapy was administered as 0.5-1.0 g/m Intermediate-dose cytarabine is an efficient treatment option for non-Langerhans cell histiocytosis patients, especially for those with CNS involvement.
Sections du résumé
BACKGROUND
Non-Langerhans cell histiocytosis, including Erdheim-Chester disease (ECD), Rosai-Dorfman disease (RDD), indeterminate cell histiocytosis (ICH), and unclassified histiocytosis, is a rare disorder lacking a standard treatment strategy. We report our experience using intermediate-dose cytarabine as the first or subsequent therapy in non-Langerhans cell histiocytosis.
RESULTS
Nine ECD patients, 5 RDD patients, 1 ICH patient and 1 unclassified histiocytosis patient were enrolled. Intermediate-dose cytarabine therapy was administered as 0.5-1.0 g/m
CONCLUSIONS
Intermediate-dose cytarabine is an efficient treatment option for non-Langerhans cell histiocytosis patients, especially for those with CNS involvement.
Identifiants
pubmed: 35130950
doi: 10.1186/s13023-022-02193-0
pii: 10.1186/s13023-022-02193-0
pmc: PMC8822720
doi:
Substances chimiques
Cytarabine
04079A1RDZ
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
39Informations de copyright
© 2022. The Author(s).
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Ann Hematol. 2020 May;99(5):1157-1159
pubmed: 32236734
JAMA Oncol. 2017 Sep 1;3(9):1253-1256
pubmed: 28253394
Nature. 2019 Mar;567(7749):521-524
pubmed: 30867592
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Br J Haematol. 2018 Nov;183(3):520-524
pubmed: 29082516
Blood. 2012 Sep 27;120(13):2700-3
pubmed: 22879539
Blood. 2016 Jun 2;127(22):2672-81
pubmed: 26966089
Ann Hematol. 2018 Jan;97(1):185-187
pubmed: 28831599
Semin Arthritis Rheum. 2012 Jun;41(6):907-13
pubmed: 22300602
Orphanet J Rare Dis. 2019 Jan 10;14(1):11
pubmed: 30630516
Haematologica. 2020 Jan 31;105(2):348-357
pubmed: 31004029
Blood. 2018 Jun 28;131(26):2877-2890
pubmed: 29720485
Leukemia. 2022 Feb;36(2):573-576
pubmed: 34611301
JAMA Oncol. 2018 Mar 1;4(3):384-388
pubmed: 29188284
Blood. 2020 May 28;135(22):1929-1945
pubmed: 32187362
Acta Oncol. 2020 Mar;59(3):302-305
pubmed: 31559889
Ann Hematol. 2016 Apr;95(5):745-50
pubmed: 26858028
Blood. 2010 Sep 16;116(11):1919-23
pubmed: 20519626